Acipimox

Active ingredient description

Acipimox inhibits the release of fatty acids from adipose tissue and reduces the blood concentrations of very low density lipoproteins (VLDL or Pre-beta) and low density lipoproteins (LDL or beta) with a subsequent overall reduction in triglyceride and cholesterol levels.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
C10AD06
Acipimox
C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AD Nicotinic acid and derivatives
Discover more medicines within C10AD06

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
OLBETAM Capsule
Summary of Product Characteristics (SPC)
UK

Medicines

Acipimox is the active ingredient of these drugs:

Drug
Countries
NEDIOS

Netherlands

OLBETAM

Netherlands New Zealand Singapore South Africa United Kingdom

Structural formula

Graphic representation of the active ingredient's molecular structure

Chemical formula: C₆H₆N₂O₃
Molecular mass: 154.125 g/mol

External identifiers

CAS Substance: 51037-30-0
DrugBank Drug: DB09055
KEGG Drug: D07190
PubChem Compound: 5310993
RxNorm Ingredient: 16817
SNOMED-CT Concept: 391711008
Acipimox (substance)
UNII Identifier: K9AY9IR2SD
ACIPIMOX
 
Next: Usage >